Posted by Michael Wonder on 04 Jan 2016

CADTH calls for patient input on a resubmission from BioMarin for Kuvan

CADTH

4 January 2016 - CADTH has received notice of a pending submission from BioMarin for sapropterin dihydrochloride (Kuvan) for use by patients with phenylketonuria.

For more details, go to: https://www.cadth.ca/sapropterin-dihydrochloride-13

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Health technology assessment , Orphan drug , Canada , Submission